Purpose The coagulation activation leads to thrombotic complications such as venous
thromboembolism (VTE) in patients with coronavirus disease‐2019 (COVID‐19) …

Abstract Infection with SARS-CoV-2 (COVID-19) can cause prothrombotic complications. We
aim to study the frequency of thrombotic complications and impact of anticoagulation on …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Background: Hypercoagulability may be a key mechanism of death in patients with
coronavirus disease 2019 (COVID-19). Objective: To evaluate the incidence of venous …

Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with
increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …